Latest News
Humacyte, Inc.
- V012 clinical trial from Humacyte targets improved dialysis access for women
- Humacyte reports positive trial results for dialysis access device By Investing.com
- Humacyte reports positive trial results for dialysis access device By Investing.com
- Humacyte to present interim Phase 3 V012 trial results for ATEV in women on dialysis
- Symvess demand accelerates as hospital orders jump 44 percent for Humacyte
- Humacyte reports 44% jump in hospitals ordering Symvess in Q3
- Humacyte Phase 3 V012 trial results of ATEV in hemodialysis access to be presented
- Humacyte’s phase 3 dialysis access trial results to be presented By Investing.com
- Form 4 Humacyte Inc For: 10 October By Investing.com
- Humacyte Adds Scott Coward and Paul Kuznik to Board Ahead of Dialysis Launch
- Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
- Form 8K Humacyte Inc For: 28 September By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →